Healthcare
Simulations Plus, Inc.(SLP)
Live Price
Offline$18.24
-0.05% today
Window Change
+9.16%
Window
May 28, 2026 โ Jun 18, 2026
- Market Cap
- $300.00M
- Revenue Growth
- +13.1%
- EPS Growth
- -744.0%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars ยท May 28, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Simulations Plus, Inc. (SLP) is a Healthcare stock with a market cap of $300.00M and listed on NASDAQ. The stock last traded around $18.24 and up 9.2% across the available one-year price window (May 28, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +13.1%, EPS growth of -744.0%, a dividend yield of 0.0%. What stands out right now is revenue +13.1%, EPS -744.0%, free cash flow +36.5% with operating margin -83.5% and ROIC -47.4%. Valuation is more restrained than many high-expectation growth names at price/sales 3.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SLP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+13.1% vs +7.6% peer median
Operating Margin
Below sector median
-83.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 9, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +13.1% and EPS is at -744.0%, with operating margin around -83.5%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLP
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SLP Max Drawdown
-10.43%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SLP and SPY.
Company Overview
Simulations Plus, Inc.
NASDAQ Global Select
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
- Leadership
- Shawn O'Connor
- IPO Date
- Jun 18, 1997
- Employees
- 243
- Street Address
- 42505 Tenth Street West
- Mailing
- Lancaster, CA, 93534-7059
- Region
- Lancaster, CA, US
- Reporting Currency
- USD
- Investor Line
- 661 723 7723
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 16.4
- Price/Sales
- 3.7
- Price/Book
- 2.2
Growth
- Revenue
- +13.1%
- EPS
- -744.0%
- Free Cash Flow
- +36.5%
Profitability
- Gross Margin
- 62.0%
- Operating Margin
- -83.5%
- Net Margin
- -78.0%
- ROE
- -49.3%
- ROIC
- -47.4%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 5.47
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.